BRPI0906044A2 - "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas" - Google Patents

"mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas"

Info

Publication number
BRPI0906044A2
BRPI0906044A2 BRPI0906044-8A BRPI0906044A BRPI0906044A2 BR PI0906044 A2 BRPI0906044 A2 BR PI0906044A2 BR PI0906044 A BRPI0906044 A BR PI0906044A BR PI0906044 A2 BRPI0906044 A2 BR PI0906044A2
Authority
BR
Brazil
Prior art keywords
tnfrp75
fusion protein
soluble mutant
pharmaceutical compositions
dna sequences
Prior art date
Application number
BRPI0906044-8A
Other languages
English (en)
Inventor
Yanjun Liu
Fang Wu
Jinsong Wu
Tong Yang
Yijun Shen
Original Assignee
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd
Taizhou Fudan Zhangjiang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd, Taizhou Fudan Zhangjiang Pharmaceutical Co Ltd filed Critical Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd
Publication of BRPI0906044A2 publication Critical patent/BRPI0906044A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0906044-8A 2008-05-30 2009-01-12 "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas" BRPI0906044A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA200810038410XA CN101591388A (zh) 2008-05-30 2008-05-30 一种可溶性tnf受体突变体
PCT/CN2009/000037 WO2009143689A1 (zh) 2008-05-30 2009-01-12 一种可溶性tnf受体突变体

Publications (1)

Publication Number Publication Date
BRPI0906044A2 true BRPI0906044A2 (pt) 2015-07-07

Family

ID=41376564

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906044-8A BRPI0906044A2 (pt) 2008-05-30 2009-01-12 "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas"

Country Status (10)

Country Link
US (1) US8454969B2 (pt)
EP (1) EP2221314B1 (pt)
JP (1) JP5445975B2 (pt)
KR (1) KR101243951B1 (pt)
CN (2) CN101591388A (pt)
AU (1) AU2009253623B2 (pt)
BR (1) BRPI0906044A2 (pt)
CA (1) CA2710040C (pt)
RU (1) RU2478645C2 (pt)
WO (1) WO2009143689A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101273893B1 (ko) 2010-09-13 2013-06-14 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
JP5819439B2 (ja) 2010-12-23 2015-11-24 ハノル バイオファーマ カンパニー リミテッド 修飾されたヒト腫瘍壊死因子受容体−１ポリペプチドまたはその断片及びその製造方法
US9580490B2 (en) 2012-06-21 2017-02-28 Hanall Biopharma Co., Ltd. Uses of modified human tumor necrosis factor receptor-1 polypeptide
CN104561022B (zh) * 2014-12-22 2017-05-17 南京师范大学 家猪肿瘤坏死因子突变体的构建及蛋白表达纯化方法
CN108853482A (zh) * 2017-05-12 2018-11-23 上海复旦张江生物医药股份有限公司 一种重组人TNFR-Fc融合蛋白突变体的用途
JP2022501388A (ja) * 2018-09-19 2022-01-06 ラホヤ インスティチュート フォー イミュノロジー 関節リウマチにおけるｐｔｐｒｓ及びプロテオグリカン
US20240043551A1 (en) * 2020-12-11 2024-02-08 Adlai Nortye Biopharma Co., Ltd. Anti-tnfr2 antibody and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514079A (ja) * 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
IL130608A0 (en) * 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
CN1246337C (zh) * 2002-11-26 2006-03-22 广州绿阳生物工程有限公司 新型TNFR－Fc融合蛋白
CN100509847C (zh) * 2003-08-01 2009-07-08 安美基公司 结晶肿瘤坏死因子受体2多肽
CN101085813B (zh) * 2006-06-05 2012-01-25 上海复旦张江生物医药股份有限公司 一种可溶性tnf受体突变体
CN101003575A (zh) * 2007-01-12 2007-07-25 中国医学科学院血液学研究所泰达生命科学技术研究中心 人肿瘤坏死因子可溶性受体Ⅱ－抗体Fc段融合蛋白

Also Published As

Publication number Publication date
AU2009253623A1 (en) 2009-12-03
RU2010141916A (ru) 2012-04-20
RU2478645C2 (ru) 2013-04-10
US8454969B2 (en) 2013-06-04
KR20100135706A (ko) 2010-12-27
JP2011511627A (ja) 2011-04-14
WO2009143689A1 (zh) 2009-12-03
CA2710040A1 (en) 2009-12-03
AU2009253623B2 (en) 2013-08-22
EP2221314B1 (en) 2013-07-03
JP5445975B2 (ja) 2014-03-19
EP2221314A1 (en) 2010-08-25
CN101591388A (zh) 2009-12-02
US20110117082A1 (en) 2011-05-19
CN101883787B (zh) 2014-09-10
KR101243951B1 (ko) 2013-03-13
CA2710040C (en) 2013-05-28
EP2221314A4 (en) 2010-12-29
CN101883787A (zh) 2010-11-10

Similar Documents

Publication Publication Date Title
IL194482A0 (en) Rage fusion proteins, formulations, and methods of use thereof
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0812575A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BRPI0914549A2 (pt) produção, formulação de usos de formulações estáveis de proteína harpina líquidas
EP3372617C0 (en) BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS FOR PREPARING AND USING THEM
BRPI0906044A2 (pt) "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas"
IL202443B (en) Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid
ZA200900345B (en) Preparation of pharmaceutical formulations
IL195491A (en) Pharmaceutical compositions of tmc278 and processes for their preparation
PT1971366E (pt) Anticorpos humanos anti-il-23, composições, métodos e usos
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
CR10619A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2155792A4 (en) PROTEIN G-OLIGONUCLEOTIDE CONJUGATE
IL184558A0 (en) Sustained release composition of protein drug
EP2118275A4 (en) ADP-ribosyltransferase FUSION PROTEIN VARIATIONS
IL186258A0 (en) Chimeric proteins, their preparation and pharmaceutical compositions containing them
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
FR2927625B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL